| Literature DB >> 35371826 |
Samicchya Adhikari1, Nejla Ghane2, Marisa Ascencio2, Tiffany Abrego2, Kapil Aedma1.
Abstract
Childhood-onset schizophrenia (COS) is a rare disorder in which symptoms of schizophrenia occur before the age of 13 years. This disorder often has a complicated presentation that can mimic other childhood disorders including post-traumatic stress disorder (PTSD), autism spectrum disorder (ASD), major depressive disorder (MDD) with psychosis, and generalized anxiety disorder (GAD) among others. This is further complicated by the low prevalence rate of COS which limits understanding of the disorder. Accurate and timely diagnosis is crucial as failure to do so has adverse implications for long-term treatment outcomes and prognosis. In this study, a rare case of a 12-year-old girl with childhood-onset schizophrenia and key findings that help differentiate it from other childhood disorders are reviewed to guide diagnosis and treatment.Entities:
Keywords: autism spectrum disorder; childhood-onset schizophrenia; intellectual disability; major depressive disorder with psychotic features; schizophrenia
Year: 2022 PMID: 35371826 PMCID: PMC8958114 DOI: 10.7759/cureus.22594
Source DB: PubMed Journal: Cureus ISSN: 2168-8184
Patient medical workup
Ab: antibody; AGNA-1: anti-glial nuclear antibody type 1; CSF: cerebrospinal fluid; AMPA-R: alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate receptor; CBA: cell-based assay; ANA: antinuclear antibody; ANNA: anti-neuronal nuclear antibody; CASPR2: anti-contactin-associated protein-like 2; CRMP-5-IgG: collapsin response mediator protein 5, IgG subtype; CRP: c-reactive protein; DPPX: dipeptidyl-peptidase-like protein type 6; IFA: indirect fluorescent antibody; dsDNA: double-stranded deoxyribonucleic acid; ESR: elevated sedimentation rate; GABA-B-R: gamma-aminobutyric acid B receptor; GAD65: glutamic acid decarboxylase 65; GFAP: glial fibrillary acidic protein; IgLON5: immunoglobulin-like cell adhesion molecule 5; LGI1 IgG: leucine-rich glioma inactivated protein 1, IgG subtype; MGLUR: metabotropic glutamate receptor; NIF: neuronal intermediate filament; NMDA-R: N-methyl-D-aspartate receptor; PCA: Purkinje cell cytoplasmic antibody; TR: anti-Tr antibody; RBC: red blood cell count; RPR: rapid plasma reagin; SS-B/La: Sjögren’s syndrome B and La antibodies; U/A: urine analysis; UDS: urine drug screen
| Lab | Patient Value | Reference Range |
| AGNA-1, CSF | <1:2 titer (negative) | <1:2 titer |
| Aminolevulinic acid, plasma | <0.2 nmol/mL | <0.5 nmol/mL |
| AMPA-R Ab CBA, CSF | Negative | Negative |
| Amphiphysin Ab, CSF | <1:2 titer (negative) | <1:2 titer |
| ANA | <1:80 titer (positive) | <1:40 titer |
| ANNA-1, CSF | <1:2 titer (negative) | <1:2 titer |
| ANNA-2, CSF | <1:2 titer (negative) | <1:2 titer |
| ANNA-3, CSF | <1:2 titer (negative) | <1:2 titer |
| ASO | <13 (IU)/mL | 0-408 (IU)/mL |
| CASPR2 IgG CBA, CSF | Negative | Negative |
| Ceruloplasmin | 23 mg/dL | 20-60 mg/dL |
| Copper, serum | 0.94 mcg/mL | 0.75-1.45 mcg/mL |
| Coproporphyrin, urine | 46 nmol/L | <110 nmol/L |
| Cortisol, AM | 14 mcg/dL | 4 TO 19 mcg/dL |
| CRMP-5-IgG | <1:2 titer (negative) | <1:2 titer |
| CRP | <0.3 mg/dL | 0-0.4 mg/dL |
| DPPX Ab IFA | Negative | Negative |
| dsDNA Ab | <1.0 (IU)/mL | <4.1 (IU)/mL |
| ESR | 35 mm/h | 0-19 mm/h |
| GABA-B-R Ab CBA, CSF | Negative | Negative |
| GAD65 Ab assay, CSF | 0.00 nmol/L | ≤0.02 nmol/L |
| GFAP IFA, CSF | Negative | Negative |
| Glucose, CSF | 54 mg/dL | 40-70 mg/dL |
| Heptacarboxylporphyrins, urine | <1 nmol/L | <7 nmol/L |
| Hexacarboxylporphyrins, urine | <1 nmol/L | <2 nmol/L |
| IgLON5 IFA, CSF | Negative | Negative |
| Lead | <0.3 mcg/dL | <5.0 mcg/dL |
| LGI1 IgG CBA, CSF | Negative | Negative |
| MGLUR1 Ab IFA, CSF | Negative | Negative |
| NIF IFA, CSF | Negative | Negative |
| NMDA-R CBA, CSF | Negative | Negative |
| PCA-1, CSF | <1:2 titer (negative) | <1:2 titer |
| PCA-2, CSF | <1:2 titer (negative) | <1:2 titer |
| PCA-TR, CSF | <1:2 titer (negative) | <1:2 titer |
| Porphobilinogen, plasma | <0.1 nmol/mL | <0.5 nmol/mL |
| Porphobilinogen, urine | 0.3 mcmol/L | ≤1.3 mcmol/L |
| Protein, CSF | 27.3 mg/dL | 12-60 mg/dL |
| RBC, CSF | 0.00 units/mm | 0.00 units/mm |
| Ribosomal P protein Ab | <0.2 Al | <1.0 AI |
| RPR | Negative | Negative |
| SS-B | 2.8 AI | <1.0 AI |
| T4 | 0.8 ng/dL | 0.7-1.9 ng/dL |
| TSH | 1.432 mlU/L | 0.300-5.000 mIU/L |
| Thyroglobulin Ab | 116 IU/ML | 10-60 IU/ML |
| Thyroperoxidase Ab | 3149 IU/ML | 15-60 IU/ML |
| Thyrotropin receptor Ab | <1.00 IU/L | 0.00-1.75 IU/L |
| U/A | ||
| UDS | Negative | Negative |
| Urinary copper, 24 hour | 9 mcg/24 hours | Not established for this age range |
| Uroporphyrin, urine | 3 nmol/L | ≤30 nmol/L |
Figure 1This drawing was completed by the patient after a prompt to draw a house, a tree, and a person